Artificial intelligence news.
Straight from the original announcements.

Racura Cleared to Raise RC220 Dose to 100 mg/m2 in HARNESS-1 Lung Cancer Trial

October 12, 2026, 13:00By the AI News Bites Editorial TeamSource: PR Newswire

The Safety Review Committee for Racura Oncology's HARNESS-1 trial has cleared the drug RC220 to move to the next planned dose level of 100 mg/m2, after finding no dose-limiting toxicities or treatment-related safety concerns in either Cohort 1 patient. The Phase 1a/b study tests RC220 together with osimertinib in patients with EGFR-mutant non-small cell lung cancer.

Key points
  • The HARNESS-1 Safety Review Committee found no dose-limiting toxicities or treatment-related safety concerns in either Cohort 1 patient.
  • RC220 is cleared to escalate from 50 mg/m2 to 100 mg/m2, combined with osimertinib at 80 mg daily.
  • Cohort 1 added a second patient after Grade 2 colitis was seen in the first patient outside the safety period.
  • The announcement contains no data on clinical activity of RC220 in EGFR-mutant NSCLC.
  • The dose-escalation stage is expected to include 12 to 40 patients, followed by a randomized Phase 1b expansion with 40 patients.

Safety review clears the next dose level

Racura Oncology Limited (ASX: RAC) said the Safety Review Committee (SRC) reviewed all safety data from both Cohort 1 patients. They received RC220 at 50 mg/m2 by intravenous infusion, combined with osimertinib at 80 mg daily. According to the company, no dose-limiting toxicities or treatment-related safety concerns were identified in either patient during the safety observation period.

The second Cohort 1 patient has now received three doses of RC220, given 21 days apart, without any such events. Pre-screening is underway to enroll the single patient in Cohort 2, who is expected to receive RC220 at 100 mg/m2 with osimertinib at 80 mg daily.

Racura stressed that the SRC clearance relates to safety and dose escalation only. The announcement does not include data on the clinical activity of RC220 in this indication.

Why Cohort 1 had two patients

Cohort 1 enrolled two patients because the SRC asked for a second patient to receive RC220 at 50 mg/m2. That followed an observation of Grade 2 colitis in the first patient outside the trial safety period. Racura said the cause was undetermined, but a contribution from RC220 could not be excluded. The second patient has reported no colitis or other dose limiting symptoms after three separate RC220 doses.

Chief Executive Officer Daniel Tillett, Ph.D., called the clearance "an important early milestone for the trial" that "reflects the disciplined execution of our clinical development plan." He also thanked the patients, their families, Principal Investigator Associate Professor Surein Arulananda and the Monash Health team.

How HARNESS-1 is designed

HARNESS-1 (RAC-020) is a multicenter study in patients with EGFR-mutant NSCLC who receive osimertinib. It includes an observational screening stage that uses circulating tumor DNA (ctDNA) to help identify eligible patients and characterize tumor molecular status before treatment.

The Phase 1a dose-escalation stage gives RC220 by intravenous infusion on Day 1 of each 21-day cycle, alongside standard-of-care maintenance osimertinib. It uses an accelerated titration design in which the first three dose levels, 50 mg/m2, 100 mg/m2 and 150 mg/m2, are each tested in a single-patient cohort. Each patient is monitored for 21 days, and the SRC reviews all available safety data before the trial moves up. According to Racura, this lets the trial pass through lower doses that may sit below the expected active range while limiting exposure to higher doses before safety data are reviewed.

Subject to the protocol and safety outcomes, the trial is expected to switch after the 150 mg/m2 cohort to a Bayesian Optimal Interval (BOIN) design. It would start at 200 mg/m2 with at least three patients per dose level, to identify the maximum tolerated dose and an appropriate dose for further study. Between 12 and 40 patients are expected in the dose-escalation stage.

After review of safety and pharmacokinetic data, the study is expected to move into a double-blind, randomized Phase 1b expansion stage. There, 40 patients will receive one of two RC220 dose levels with osimertinib and be monitored for safety, pharmacokinetics and early signals of clinical activity, including progression-free survival, overall survival, ctDNA dynamics and changes in cancer-specific mutations.

The scientific rationale and what comes next

Racura notes that EGFR-mutant NSCLC is initially sensitive to EGFR inhibition, but responses to EGFR tyrosine kinase inhibitors such as osimertinib (Tagrisso; AstraZeneca) are typically limited by acquired resistance. The company lists mechanisms including secondary EGFR alterations, bypass receptor tyrosine kinase activation, MAPK/PI3K pathway reactivation, oncogenic fusions, lineage plasticity, epithelial-to-mesenchymal transition and histologic transformation.

RC220 is a proprietary formulation of (E,E)-bisantrene, designed to overcome solubility issues that prevent safe peripheral intravenous infusion. According to the company, it targets G-quadruplex DNA and RNA structures in oncogenic regulatory regions, and stabilizing them can disrupt control networks that sustain malignant proliferation, including MYC-driven growth and survival pathways.

For now, the news is an early safety step: the trial can proceed to 100 mg/m2 once the Cohort 2 patient is enrolled. Whether RC220 adds anything to osimertinib remains untested in the data released. Trial details, including recruiting sites, are listed in the Australian New Zealand Clinical Trials Registry under ACTRN12626000325303.

Racura OncologyRC220HARNESS-1osimertinibMonash Healthhealthcareresearch findings

Related news

Ascletis reports preclinical results for oral and long-acting obesity drugs
ResearchNovember 16, 2026, 10:10

Ascletis reports preclinical results for oral and long-acting obesity drugs

Ascletis Pharma has presented preclinical results for an oral GLP-1R and GIPR combination and a long-acting triple agonist aimed at obesity treatment. The company said…

SAS and Posit Partner on Governed AI for Life Sciences
BusinessNovember 16, 2026, 09:00

SAS and Posit Partner on Governed AI for Life Sciences

SAS and Posit PBC have formed a partnership to give life sciences organizations more flexibility in using SAS and open-source technologies, initially for clinical…

Research
ResearchNovember 12, 2026, 13:00

Racura links bisantrene’s active isomer to MYC gene silencing

Racura Oncology has presented preclinical data identifying (E,E)-bisantrene as the major active isomer responsible for stabilizing the MYC G-quadruplex and reducing MYC…